A recent meta-analysis and meta-regression of 13 randomized clinical trials by Mocking et al.
differences and s.e.'s reported in their Figure 1 , we found that the studies included in Mocking et al. 1 show an inverse association between study effect size and study precision (r = − 0.344): less precise trials produced larger effect sizes. To illustrate the impact that less precise studies can have on meta-analytic results, we repeated the meta-analysis (based on the data provided in Mocking et al.
1
) but without the least precise study 3 (N = 20), which reduced the overall effect size from a standardized mean difference (SMD) of 0.398 (95% confidence interval (CI): 0.114, 0.681, P = 0.006) to 0.317 (95% CI: 0.051, 0.582, P = 0.019). In addition, excluding the second-least precise study 4 (N = 22) further reduces the effect size to 0.227 (95% CIs: 0.001, 0.453, P = 0.049). Thus, the observed effect of omega-3 fatty-acid supplementation on depression seems largely driven by the most imprecise studies.
META-REGRESSION: THE MORE TRIALS THE MERRIER
Based on nine univariate meta-regressions (one for each study characteristic) across 13 trials, Mocking et al. 1 concluded that omega-3 fatty-acid supplementation in MDD patients is especially beneficial in patients using antidepressants and for higher doses of EPA. A low number of trials reduces the probability of a truenegative finding. Whereas the number of trials here may not be exceptionally low compared with other meta-regressions, detecting moderator effects requires more powerful analyses than are employed in most published studies. 5 Especially when high heterogeneity is present across studies, as is the case in Mocking et al. 1 (I 2 = 73%, t 2 = 0.171), power of 80% to detect even the largest of the modest moderator effects reported in Mocking et al. 1 may not be achieved except with a much larger number of trials. 5 Perhaps counterintuitively, low statistical power also decreases the probability that an observed effect that reaches nominal statistical significance actually reflects a true effect. 6, 7 The risk of false-positive findings is further increased by the substantial number of statistical tests conducted in this study. 7, 8 Indeed, neither of the results (antidepressants, P = 0.044; EPA dose, P = 0.009) survives correction for multiple comparisons (Bonferroni Figure 1 . Dose-response relationship. Circles represent the effect size of the individual trials scaled by their sample size. The gray circles represent the studies by Nemets et al. 3 and Su et al. 4 (top right), which have the smallest sample sizes and the largest effect sizes. The doseresponse relationship is depicted as a solid line for the linear trend based on all trials (r = 0.6) and a gray line discarding Nemets et al. 3 and Su et al. 4 (r = 0.1). EPA, eicosapentaenoic acid.
P-value = 0.05/9 = 0.006), and the EPA dose-response relationship is mainly attributable to the two least precise studies 3,4 ( Figure 1 ).
META-REGRESSION: CORRELATION IS NOT CAUSATION
The conclusions on EPA dose and antidepressant use were not based on randomization of these characteristics. Meta-regression is observational and, therefore, susceptible to confounding; it does not allow causal inference. 8 Hence, the associations found with EPA dose and antidepressant use could be due to other, known or unknown, trial characteristics. That findings from this meta-regression do not necessarily align with results from intervention studies is illustrated by the largest clinical trial available to date (N = 432), 9 which stratified randomization by antidepressant use and found evidence for neither an interaction between treatment group and antidepressant use, nor benefit from EPA supplementation among the subgroup of patients also taking antidepressants (n = 174).
Meta-analyses are critical to evidence-based medicine, but may lead to biased conclusions if the quality of available evidence is not adequately considered. Findings from meta-regression should be interpreted with particular caution, especially when suggesting clinical implications. Even if unbiased, a statistically significant result is not necessarily clinically relevant, and one may wonder whether, for instance, a decrease of 0.04 on the 17-item Hamilton Depression Rating Scale with every 100 mg increase in EPA dose is meaningful. In our view, the current evidence supporting the use of omega-3 fatty-acid supplementation in depression remains weak and clinical implications should be tempered.
